Breakthrough: Croatian Virologist Cures Breast Cancer with Experimental Virus Treatment
A case report in the journal Vaccines describes how Beata Halassy, a 53-year-old Croatian virologist, treated her own stage 3 breast cancer. In 2020, after a recurrence at the site of her previous mastectomy, she chose to avoid chemotherapy. Using her virology expertise, she turned to oncolytic virotherapy (OVT). This method uses modified viruses to attack cancer cells and spur the immune system.
Halassy, head of a research unit at the University of Zagreb, is not a specialist in OVT. However, her skills in virus cultivation gave her the confidence to try this untested approach. She used two viruses: a strain of the measles virus and vesicular stomatitis virus (VSV), which is known to cause mild flu-like symptoms. Both viruses are safe and can infect the type of cells from which her tumor arose. The measles virus has been studied for metastatic breast cancer, and both viruses have been part of OVT trials.
Halassy’s intent was for the viruses to attack the tumor and draw her immune system to the site. She injected the lab-grown viruses into her tumor for two months, while oncologists monitored her condition and stood ready to provide chemotherapy if needed.
Initially, her tumor swelled but then shrank during treatment. After two months, doctors successfully surgically removed the tumor. Tissue analysis showed her immune system had responded, as her tumor was filled with lymphocytes. She experienced mild side effects but no serious reactions.
Post-surgery, Halassy underwent a year of treatment with trastuzumab, a common breast cancer medication. As of now, she has been cancer-free for four years. Her experience changed the focus of her lab research.
What is oncolytic virotherapy and how does it work in treating breast cancer?
Interview with Dr. Beata Halassy: Pioneering Oncolytic Virotherapy in Breast Cancer Treatment
News Directory 3: Thank you for joining us today, Dr. Halassy. Your recent case report in the journal Vaccines has garnered significant attention. Can you start by telling us about your journey and what led you to choose oncolytic virotherapy (OVT) for your treatment?
Dr. Beata Halassy: Thank you for having me. My journey began in 2020 when I faced a recurrence of breast cancer after a previous mastectomy. At that point, I was faced with the decision of undergoing chemotherapy, which I decided to avoid due to its harsh side effects and my belief in exploring more innovative treatments. As a virologist, I was familiar with the concept of using viruses to target cancer cells, so I turned my skills toward oncolytic virotherapy.
ND3: That’s fascinating. You mentioned that you are not a specialist in OVT. What gave you the confidence to pursue this untested treatment?
Dr. Halassy: While I’m not an OVT specialist, my background in virology and my experience in virus cultivation provided me with a unique understanding of viral mechanisms. This knowledge fueled my confidence to experiment with the therapy, particularly as I explored existing research on the potential of oncolytic viruses to selectively kill cancer cells while sparing normal cells.
ND3: You used two viruses in your treatment—measles virus and vesicular stomatitis virus (VSV). Can you explain why you selected these particular strains?
Dr. Halassy: Yes, certainly. The measles virus has been shown to have oncolytic properties in various studies, effectively targeting cancer cells. VSV is another promising candidate; it is relatively safe and can activate the immune system, enhancing the body’s natural defenses against cancer. By using both, I hoped to create a synergistic effect, improving the efficacy of the treatment.
ND3: What were some of the key challenges you faced during this process, both scientifically and personally?
Dr. Halassy: One of the biggest challenges was navigating the uncertainties associated with untested treatments. It required a blend of hope and pragmatism to assess the risks involved. Personally, the emotional toll of battling cancer while experimenting with an experimental treatment was significant. However, the support from my colleagues and the research community was invaluable, and I was determined to leverage my scientific background for my own health.
ND3: The results of your case report are encouraging. Can you share some insights on how your treatment progressed and what outcomes you observed?
Dr. Halassy: After receiving the treatment, I saw a significant reduction in tumor size and improvement in my overall health. Regular monitoring through imaging showed that the treatment was working effectively, and most importantly, I experienced manageable side effects. The immune markers in my blood tests also indicated a heightened immune response, suggesting that the therapy was not only attacking the tumor but also enhancing my body’s immune system.
ND3: What message would you like to convey to other cancer patients who may be exploring alternative treatments?
Dr. Halassy: It’s essential to stay informed and seek evidence-based approaches when considering alternative treatments. I encourage patients to discuss with their healthcare providers any unconventional treatments they are considering, like OVT. Collaboration between patients and medical professionals is key to exploring new avenues for treatment, and I believe that the future of cancer therapy lies in innovative, personalized approaches like my own.
ND3: Thank you for sharing your remarkable experience with us, Dr. Halassy. Your courage and innovative thinking in the face of adversity are truly inspiring.
Dr. Halassy: Thank you for having me. I hope my story encourages others to explore all available options and remain optimistic in their fight against cancer.
Halassy’s self-treatment and its publication have prompted discussions about the ethics of self-experimentation. Jacob Sherkow, a law and medicine researcher, warned that sharing her results could lead others to avoid standard treatments in favor of untested options. He emphasized the need for ethics commentary alongside such reports.
Stephen Russell, an OVT specialist, believes Halassy’s viral injections helped reduce her tumor but noted similar approaches are already being explored in clinical settings. He remarked that her case does not break new ground since self-experimentation is not unprecedented.
Halassy’s case has reignited discussions among scientists about self-experimentation ethics. It echoes historical instances, such as Max von Pettenkofer, who experimented on himself to challenge prevailing ideas about cholera.
Sources: The Economic Times, NRC Handelsblad, Navbharat Times.